Abstract: Disclosed herein are compounds of Formula (I): and pharmaceutically acceptable salts thereof, related pharmaceutical compositions, and methods for using the same to treat parasitic diseases.

Abstract: Disclosed herein are compounds of Formula (1): and pharmaceutically acceptable salt thereof, related pharmaceutical compositions, and methods for using the same to treat parasitic diseases.

Abstract: The present invention is directed to a novel B. microti-based promoter and expression system. The present invention is also directed to a novel method of transfecting B. microti by electroporation, the resulting transfected B. microti parasite cell lines, and optionally, B. microti transfected with a particular novel promoter. In some embodiments, transgenic B. microti parasites that express reporter genes and their uses are provided. In certain embodiments, a multi-functional promoter controls multiple genes, e.g. a bifunctional promoter may control a gene of interest and a reporter or selection gene. The promoter may be particularly useful to control expression of apicomplexan genes and form apicomplexan proteins, e.g., without limitation, those of Babesia parasites. In embodiments, expression systems comprising the promoter are provided. In certain embodiments, B. microti-based systems that express reporter genes are provided.

Abstract: The present invention relates to the treatment and prevention of malaria infection. In particular, the present invention provides novel noninfectious, whole organism vaccines for malaria, which vaccines comprise a Plasmodium axenic liver stage. The invention also provides methods to treat and prevent malaria by administering such Plasmodium axenic liver stage vaccines, as well as methods to generate Plasmodium axenic liver stages.